Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.

Rheumatology (Oxford, England)

Volumn 49, Issue 4, 2010, Pages 733-740

  Saraux, Alain ^a   Gossec, Laure ^b   Goupille, Philippe ^b   Bregman, Bruno ^b   Boccard, Eric ^b   Dupont, Danielle ^b   Beresniak, Ariel ^b  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; RITUXIMAB;

ALGORITHM; ARTICLE; BIOLOGICAL MODEL; COST BENEFIT ANALYSIS; DRUG COST; ECONOMICS; FRANCE; HOSPITALIZATION; HUMAN; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

ALGORITHMS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST-BENEFIT ANALYSIS; DRUG COSTS; FRANCE; HUMANS; IMMUNOCONJUGATES; MODELS, BIOLOGICAL; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 79952396885     PISSN: None     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep434     Document Type: Article

References (0)